Advertisement
Screener

GAIN THERAPEUTICS, INC (GANX) Income (Loss) from Continuing Operations before Income Taxes, Domestic

GAIN THERAPEUTICS, INC Income (Loss) from Continuing Operations before Income Taxes, Domestic

GAIN THERAPEUTICS, INC (GANX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$22.48 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.

Financial Statements › Income Statement › Pre-tax Income

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-26

  • GAIN THERAPEUTICS, INC income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$22.48M.
  • GAIN THERAPEUTICS, INC income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$22.39M.
  • GAIN THERAPEUTICS, INC income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$22.48M.
  • GAIN THERAPEUTICS, INC income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$17.34M.
Period endIncome (Loss) from Continuing Operations before Income Taxes, Domestic 12 month
2025-12-31-$22.48M
10-K · filed 2026-03-26
2024-12-31-$22.39M
10-K · filed 2026-03-26
2023-12-31-$22.48M
10-K · filed 2025-03-27
2022-12-31-$17.34M
10-K · filed 2024-03-26
2021-12-31-$7.60M
10-K · filed 2023-03-23
2020-12-31-$623.67K
10-K · filed 2022-03-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lifevantage Corp (LFVN)United States$0.078B15.40
Adicet Bio, Inc. (ACET)United States$0.078B-0.81
Valion Bio, Inc. (VBIO)United States$0.077B
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30
iBio, Inc. (IBIO)United States$0.077B-2.94
Telomir Pharmaceuticals, Inc. (TELO)United States$0.084B
Lexaria Bioscience Corp. (LEXX)$0.084B-1.92
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
OS Therapies Inc (OSTX)United States$0.076B-2.17
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B